Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial

Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN)

Pfizer Elected to Continue Development of Tamper-resistant Painkiller Remoxy – VIVUS, ARNA, ARIA, MNKD, MRK, PFE (FiscalInsider)
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. …VIVUS, Inc. (NASDAQ:VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. The stock price has dropped 6.1% over the past month, worse than the 1.3% decrease the NASDAQ has seen over the same period of time VIVUS, Inc. (NASDAQ:VVUS) shares plunged -0.81% to $12.23 in last trading session. Stock traded in range of $12.00 – $12.41.

VIVUS, Inc. (NASDAQ:VVUS)

Onyx trials cloud Amgen deal (TheDeal)
A Bloomberg article that ran Aug. 14 cited anonymous sources saying that Amgen, Inc. (NASDAQ:AMGN)‘s $10 billion, $120 per share acquisition of Onyx Pharmaceuticals Inc. was hanging on whether Amgen could see results of a clinical trial for Onyx’s Kyprolis. However, the reference to the study results was ambiguous and left parties tracking the deal trying to figure out which trial the sources were alluding to and whether access to the data could truly be a deal-breaker.

Biotech Stocks in News, VIVUS Inc, Arena Pharmaceuticals Inc, Ariad Pharmaceuticals Inc, MannKind Corporation, Affymax, Pfizer Inc (FiscalInsider)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a controversial stock among biotech investors. The bulls believe that increasing rates of global obesity will inevitably trigger more sales of its new weight loss drug, Belviq, which was approved by the FDA last June. However, the bears believe that lingering safety concerns regarding Belviq and the company’s insistence on combining the treatment with other medications could cause problems down the road. Arena shares plunged -0.44% to $6.80 in last trading session. Stock traded in range of $6.75 – $6.91.

Amgen Rating Reiterated by Goldman Sachs Group Inc. (AMGN) (WatchlistNews)
Goldman Sachs Group Inc. reiterated their buy rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report released on Friday morning, ARN reports. A number of other firms have also recently commented on AMGN. Analysts at RBC Capital raised their price target on shares of Amgen, Inc. (NASDAQ:AMGN) from $120.00 to $125.00 in a research note to investors on Thursday, August 1st. They now have an outperform rating on the stock.

Investor’s Alert -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Plug Power Inc (NASDAQ:PLUG), Targacept, Inc. (NASDAQ:TRGT), Inc. (NASDAQ:GTXI) (Techsonian)
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. …Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to keep its gain at 1.44% on below normal -average volume of 2.71M shares. The stock settled at $7.06 after floating in a range of $6.95 to $7.13. Significantly, its latest price is at a discount of -14.25% to its 200-day moving average price.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!